Brain atrophy as a non-response predictor to interferon-beta in relapsing-remitting multiple sclerosis

Neurological Research

Volumn 36, Issue 7, 2014, Pages 615-618

  Rojas, Juan Ignacio ^a   Patrucco, Liliana ^a   Miguez, Jimena ^a   Besada, Cristina ^a   Cristiano, Edgardo ^a  

^a HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

Author keywords

Brain atrophy; Interferon; MR; Multiple sclerosis; Response

Indexed keywords

BETA1A INTERFERON; BETA INTERFERON; IMMUNOLOGIC FACTOR;

ADULT; AGE; ARTICLE; BRAIN ATROPHY; CLINICAL EVALUATION; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; FEMALE; FOLLOW UP; GENDER; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; TREATMENT FAILURE; TREATMENT RESPONSE; ATROPHY; BRAIN; DISABILITY; DRUG EFFECTS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PATHOLOGY; PROGNOSIS; RISK; SENSITIVITY AND SPECIFICITY;

ADULT; ATROPHY; BRAIN; DISABILITY EVALUATION; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-BETA; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PROGNOSIS; PROSPECTIVE STUDIES; RISK; SENSITIVITY AND SPECIFICITY; TREATMENT FAILURE;

EID: 84902968878     PISSN: 01616412     EISSN: 17431328     Source Type: Journal    
DOI: 10.1179/1743132813Y.0000000304     Document Type: Article

References (17)

1. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet. 1998;352(9139):1498-504.
2. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS. Lancet. 1998;352(9139):1491-7.
3. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol. 1996;39(3):285-94.
4. Rio J, Comabella M, Montalban X. Predicting responders to therapies for multiple sclerosis. Nat Rev Neurol. 2009;5(10): 553-60.
5. Rio J, Nos C, Tintore M, Tellez N, Galan I, Pelayo R, et al. Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients. Ann Neurol. 2006;59(2):344-52.
6. Horakova D, Kalincik T, Dolezal O, Krasensky J, Vaneckova M, Seidl Z, et al. Early predictors of non-response to interferon in multiple sclerosis. Acta Neurol Scand. 2012;126(6):390-7.
7. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the 'McDonald Criteria'. Ann Neurol. 2005;58(6): 840-6.
8. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001;50(1):121-7.
9. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 1983;13(3):227-31.
10. Molyneux PD, Miller DH, Filippi M, Yousry TA, Radu EW, Ader HJ, et al. Visual analysis of serial T2-weighted MRI in multiple sclerosis: intra- and interobserver reproducibility. Neuroradiology. 1999;41(12):882-8.
11. Smith SM, de Stefano N, Jenkinson M, Matthews PM. Normalized accurate measurement of longitudinal brain change. J Comput Assist Tomogr. 2001;25(3):466-75.
12. Smith SM, Zhang Y, Jenkinson M, Chen J, Matthews PM, Federico A, et al. Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage. 2002; 17(1):479-89.
13. Cardoso L, Miasso AI, Galera SA, Maia BM, Esteves RB. Adherence level and knowledge about psychopharmacological treatment among patients discharged from psychiatric internment. Rev Lat Am Enfermagem. 2011;19(5):1146-54.
14. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med. 1998;338(5):278-85.
15. Filippi M, Rocca MA, de Stefano N, Enzinger C, Fisher E, Horsfield MA, et al. Magnetic resonance techniques in multiple sclerosis: the present and the future. Arch Neurol. 2011;68(12): 1514-20.
16. Filippi M, Rocca MA, Benedict RH, DeLuca J, Geurts JJ, Rombouts SA, et al. The contribution of MRI in assessing cognitive impairment in multiple sclerosis. Neurology. 2010;75(23):2121-8.
17. Barkhof F, Simon JH, Fazekas F, Rovaris M, Kappos L, de Stefano N, et al. MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trials. Nat Rev Neurol. 2012;8(1):13-21.